MedWatch

RNA treatments can be the next quantum leap of biotechnology

Like antibodies in the 1990s, drugs targeting RNA are approaching a major breakthrough. The main challenges have been managed, the industry and investors are excited, and the RNA field could potentially be the next billion-dollar adventure for biotech firms.

Foto: AstraZeneca/PR

In the mid-1980s, medicines agencies in EU and the US approved the first ever therapeutic antibody.

However, it took a decade before antibodies really broke through in the end of the 1990s, when EMA and FDA approved a range of the most successful antibody therapies like the rheumatism treatment Remicade and the cancer drugs Mabthera and Herceptin.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier